Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy

Patrick Rossignol; Joël Ménard; Renaud Fay; Finn Gustafsson; Bertram Pitt; Faiez Zannad

doi:10.1016/j.jacc.2011.04.049

Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy

Patrick Rossignol, Joël Ménard, Renaud Fay, Finn Gustafsson, Bertram Pitt, Faiez Zannad

119 Citations (Scopus)

Abstract

The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone's beneficial effects on cardiovascular outcomes.

Original language	English
Journal	American College of Cardiology. Journal
Volume	58
Issue number	19
Pages (from-to)	1958-66
Number of pages	9
ISSN	0735-1097
DOIs	https://doi.org/10.1016/j.jacc.2011.04.049
Publication status	Published - 2011

Keywords

Aged
Aldosterone Antagonists
Clinical Trials as Topic
Diuresis
Female
Heart Failure
Humans
Male
Middle Aged
Potassium
Spironolactone

Access to Document

10.1016/j.jacc.2011.04.049

Fingerprint

Dive into the research topics of 'Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy'. Together they form a unique fingerprint.

Cite this

Rossignol, P., Ménard, J., Fay, R., Gustafsson, F., Pitt, B., & Zannad, F. (2011). Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. American College of Cardiology. Journal, 58(19), 1958-66. https://doi.org/10.1016/j.jacc.2011.04.049

Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. / Rossignol, Patrick; Ménard, Joël; Fay, Renaud et al.
In: American College of Cardiology. Journal, Vol. 58, No. 19, 2011, p. 1958-66.

Research output: Contribution to journal › Journal article › Research › peer-review

Rossignol, P, Ménard, J, Fay, R, Gustafsson, F, Pitt, B & Zannad, F 2011, 'Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy', American College of Cardiology. Journal, vol. 58, no. 19, pp. 1958-66. https://doi.org/10.1016/j.jacc.2011.04.049

Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. American College of Cardiology. Journal. 2011;58(19):1958-66. doi: 10.1016/j.jacc.2011.04.049

Rossignol, Patrick ; Ménard, Joël ; Fay, Renaud et al. / Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. In: American College of Cardiology. Journal. 2011 ; Vol. 58, No. 19. pp. 1958-66.

@article{81f8cf8a345e4cb3b18f137336681969,

title = "Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy",

abstract = "The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone's beneficial effects on cardiovascular outcomes.",

keywords = "Aged, Aldosterone Antagonists, Clinical Trials as Topic, Diuresis, Female, Heart Failure, Humans, Male, Middle Aged, Potassium, Spironolactone",

author = "Patrick Rossignol and Jo{\"e}l M{\'e}nard and Renaud Fay and Finn Gustafsson and Bertram Pitt and Faiez Zannad",

year = "2011",

doi = "10.1016/j.jacc.2011.04.049",

language = "English",

volume = "58",

pages = "1958--66",

journal = "American College of Cardiology. Journal",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "19",

}

TY - JOUR

T1 - Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy

AU - Rossignol, Patrick

AU - Ménard, Joël

AU - Fay, Renaud

AU - Gustafsson, Finn

AU - Pitt, Bertram

AU - Zannad, Faiez

PY - 2011

Y1 - 2011

N2 - The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone's beneficial effects on cardiovascular outcomes.

AB - The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone's beneficial effects on cardiovascular outcomes.

KW - Aged

KW - Aldosterone Antagonists

KW - Clinical Trials as Topic

KW - Diuresis

KW - Female

KW - Heart Failure

KW - Humans

KW - Male

KW - Middle Aged

KW - Potassium

KW - Spironolactone

UR - https://www.scopus.com/pages/publications/80054975039

U2 - 10.1016/j.jacc.2011.04.049

DO - 10.1016/j.jacc.2011.04.049

M3 - Journal article

C2 - 22032706

SN - 0735-1097

VL - 58

SP - 1958

EP - 1966

JO - American College of Cardiology. Journal

JF - American College of Cardiology. Journal

IS - 19

ER -

Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this